Allogene (ALLO) director receives new stock options and RSU awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.
Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Belldegrun Arie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 929,913 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 263,033 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 929,913 shares (Direct);
Restricted Stock Unit — 263,033 shares (Direct);
Common Stock — 4,710,120 shares (Indirect, See footnote);
Common Stock — 2,236,816 shares (Direct)
Footnotes (1)
- The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date.
FAQ
What insider transactions did Allogene (ALLO) disclose for Arie Belldegrun?
Allogene reported that director Arie Belldegrun received a stock option for 929,913 shares at $1.87 per share and 263,033 RSUs on February 2, 2026. The filing also updates his direct and indirect common stock holdings.
How do the new stock options for Allogene (ALLO) director vest?
The stock option for 929,913 shares vests with 25% of the shares on February 2, 2027. The remaining 75% then vest in 36 equal monthly installments thereafter, aligning vesting with ongoing service over several years.
What are the vesting terms of the 263,033 RSUs granted at Allogene (ALLO)?
The 263,033 RSUs each represent a right to receive one Allogene common share. They vest in four equal annual installments starting on February 2, 2026, subject to the director’s continued service through each vesting date.